Re­vis­it­ing the 'cy­tokine stor­m' in ARDS; the painful wait for an­ti-in­flam­ma­to­ry drugs/tar­gets that solve Covid-19 deaths

Biotech Voices is a collection of exclusive opinion editorials from some of the leading voices in biopharma on the biggest industry questions today. Think you have a voice that should be heard? Reach out to Amber Tong.

I am a pul­monary and crit­i­cal care physi­cian-sci­en­tist with sub­stan­tial ex­per­tise in crit­i­cal care med­i­cine, par­tic­u­lar­ly in the in­flam­ma­to­ry path­ways in­volved in the acute res­pi­ra­to­ry dis­tress syn­drome (ARDS) and ven­ti­la­tor-in­duced lung in­jury (VILI).

As a re­sult, my lab­o­ra­to­ry has been pur­su­ing mech­a­nis­tic in­sights and ef­fec­tive ther­a­pies for ARDS and VILI for sev­er­al decades. Over this ex­pand­ed time hori­zon, there is abun­dant sup­port for the con­trib­u­to­ry role of the much dis­cussed “cy­tokine storm,” long as­so­ci­at­ed with fa­tal ARDS and now with Covid-19-as­so­ci­at­ed ARDS.

The es­sen­tial na­ture of the elab­o­rat­ed cy­tokines to Covid-19 ARDS out­comes has been ques­tioned in the me­dia and were ini­tial­ly voiced in an ed­i­to­r­i­al by UCSF ARDS ex­perts. It is ap­pro­pri­ate to con­sid­er this point of view; how­ev­er, it must be rec­og­nized that the pri­ma­ry ba­sis for this sen­ti­ment is re­lat­ed to ob­ser­va­tions cen­tered on the in­ter­leukin-6 (IL-6) path­way, well-rec­og­nized to be in­volved in ARDS patho­bi­ol­o­gy.

One ob­ser­va­tion is that me­di­an cir­cu­lat­ing IL-6 lev­els in five Covid-19 co­horts were low­er when com­pared to co­horts of non-Covid-19 ARDS, and the sec­ond ob­ser­va­tion is that sev­er­al high-pro­file tri­als tar­get­ing IL-6 re­cep­tor an­tag­o­nism in Covid ARDS failed to im­prove COVID-19 ARDS mor­tal­i­ty. Specif­i­cal­ly, the IL-6 re­cep­tor an­tag­o­nists tocilizum­ab (Roche/Sanofi) and sar­ilum­ab (Re­gen­eron/Sanofi), both failed to im­prove mor­tal­i­ty in Phase II/III clin­i­cal tri­als of Covid-19 pa­tients with se­vere dis­ease (“Cleanup on IL-6”).

In fact, tri­al ev­i­dence sug­gest­ed that drug re­cip­i­ents may be at in­creased risk for oth­er in­fec­tions, a par­tic­u­lar risk in re­gions where drug-re­sis­tant bac­te­ria are com­mon. The ac­cu­mu­lat­ed fail­ure of tar­get­ing the IL-6 path­way may re­flect sev­er­al fac­tors that are of spe­cif­ic rel­e­vance to IL-6, in­clud­ing the down­stream na­ture of this cy­tokine in the in­flam­ma­to­ry cas­cade, as well as the com­plex role of IL-6 in in­nate im­mu­ni­ty, i.e. ex­ert­ing both an­ti-in­flam­ma­to­ry and pro-in­flam­ma­to­ry ef­fects.

Over­all, I be­lieve there is wide ac­cep­tance that ARDS patho­bi­ol­o­gy is fun­da­men­tal­ly re­lat­ed to mas­sive ac­ti­va­tion of evo­lu­tion­ar­i­ly-con­served in­flam­ma­to­ry net­works by sep­sis (in­fec­tion in the blood), se­vere trau­ma, and se­vere bac­te­r­i­al or vi­ral pneu­mo­nias in­clud­ing SARS-CoV-2. This in­flam­ma­to­ry ac­ti­va­tion is sub­stan­tial­ly am­pli­fied when pa­tients are placed up­on me­chan­i­cal ven­ti­la­tion, a po­tent in­flam­ma­to­ry stim­u­lus and con­trib­u­tor to ARDS mor­tal­i­ty.

Thus, tar­get­ing of the un­remit­ting in­flam­ma­tion re­mains a crit­i­cal com­po­nent to ad­dress­ing ARDS mor­tal­i­ty, al­beit un­like­ly as a sole ther­a­peu­tic strat­e­gy. This was sup­port­ed by the Unit­ed King­dom tri­als demon­strat­ing ben­e­fit of the po­tent, non-spe­cif­ic an­ti-in­flam­ma­to­ry steroid, dex­am­etha­some, in se­vere Covid-19 ARDS.

Clear­ly, ARDS is a vex­ing dis­or­der with­out FDA-ap­proved ther­a­pies and a stag­ger­ing un­met need in the cur­rent Covid-19 pan­dem­ic land­scape. The fail­ure of many promis­ing in­flam­ma­tion-fo­cused ARDS drugs in Phase II and III tri­als, such as IL-6 an­tag­o­nists and gam­ma in­ter­fer­on ana­logues, may re­flect is­sues in: 1) tar­get se­lec­tion, i.e. cy­tokines down­stream in the in­flam­ma­to­ry cas­cade; or 2) de­lays in ad­min­is­tra­tion of the an­ti-in­flam­ma­to­ry ther­a­peu­tic, there­by re­duc­ing its in­flu­ence on damp­en­ing in­flam­ma­to­ry ac­ti­va­tion is min­i­mal.

As a physi­cian-sci­en­tist and ICU care­giv­er, I have been long search­ing for nov­el ap­proach­es to re­duc­ing ARDS mor­tal­i­ty. When serv­ing as the Di­rec­tor of Pul­monary and Crit­i­cal Care Med­i­cine at Johns Hop­kins in 2005, I first re­port­ed the iden­ti­fi­ca­tion of eNAM­PT (ex­tra­cel­lu­lar nicoti­namide phos­pho­ri­bo­syl­trans­ferase) as a mas­ter reg­u­la­tor of in­nate im­mu­ni­ty-dri­ven in­flam­ma­tion that con­tributes to ARDS mor­tal­i­ty and is es­sen­tial­ly in­volved in VILI patho­bi­ol­o­gy.

Our sub­stan­tial pre­clin­i­cal da­ta sup­port the tar­get­ing of eNAM­PT with a hu­man­ized mon­o­clon­al an­ti­body (ALT-100 mAb) to sig­nif­i­cant­ly im­pact hu­man Covid-19- and non-Covid ARDS/VILI. We are mak­ing ex­cel­lent progress in mov­ing ALT-100 mAb down the drug de­vel­op­ment pipeline and to ARDS Clin­i­cal Tri­al eval­u­a­tion.

I am to­tal­ly con­vinced that the in­creas­ing avail­abil­i­ty of nov­el strate­gies (such as ALT-100 mAb) will ul­ti­mate­ly al­low for suc­cess­ful tri­als with drugs that re­duce ARDS sever­i­ty and mor­tal­i­ty, par­tic­u­lar­ly when we be­gin to em­ploy per­son­al­ized med­i­cine strate­gies in tri­al de­sign.

I do be­lieve, how­ev­er, sim­i­lar to the man­age­ment of many can­cers, that to dra­mat­i­cal­ly move the nee­dle on re­duc­ing ARDS/VILI mor­tal­i­ty, will re­quire a com­bi­na­tion of ther­a­peu­tic ap­proach­es (in­clud­ing an an­ti-in­flam­ma­to­ry drug). The wait for an FDA-ap­proved ARDS ther­a­py or ther­a­pies has been a frus­trat­ing re­al­i­ty. I am cer­tain many will agree that giv­en the cur­rent Covid pan­dem­ic and like­li­hood of fu­ture pan­demics, we sim­ply can­not af­ford to wait any longer.

Dr. Joe G.N. Gar­cia is an elect­ed mem­ber of the Na­tion­al Acad­e­my of Med­i­cine and CEO of Aqualung Ther­a­peu­tics, an ear­ly-stage biotech com­pa­ny de­vel­op­ing an im­mune-fo­cused, an­ti-in­flam­ma­to­ry plat­form cen­tered around nov­el ther­a­peu­tic hu­man­ized an­ti­bod­ies for ARDS/VILI pa­tients.

Biotech Voic­es is a con­tributed col­umn from se­lect End­pointsNews read­ers. Read pre­vi­ous pieces here. To in­quire about sub­mis­sions, con­tact Kyle Blanken­ship at kyle@end­pointsnews.com.

Scoop: Boehringer qui­et­ly shut­ters a PhII for one of its top drugs — now un­der re­view

Boehringer Ingelheim has quietly shut down a small Phase II study for one of its lead drugs.

The private pharma player confirmed to Endpoints News that it had shuttered a study testing spesolimab as a therapy for Crohn’s patients suffering from bowel obstructions.

A spokesperson for the company tells Endpoints:

Taking into consideration the current therapeutic landscape and ongoing clinical development programs, Boehringer Ingelheim decided to discontinue our program in Crohn’s disease. It is important to note that this decision is not based on any safety findings in the clinical trials.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Vas Narasimhan (Photographer: Jason Alden/Bloomberg via Getty Images)

No­var­tis de­tails plans to axe 8,000 staffers as Narasimhan be­gins sec­ond phase of a glob­al re­org

We now know the number of jobs coming under the axe at Novartis, and it isn’t small.

The pharma giant is confirming a report from Swiss newspaper Tages-Anzeiger that it is chopping 8,000 jobs out of its 108,000 global staffers. A large segment will hit right at company headquarters in Basel, as CEO Vas Narasimhan axes some 1,400 of a little more than 11,000  jobs in Switzerland.

The first phase of the work is almost done, the company says in a statement to Endpoints News. Now it’s on to phase two. In the statement, Novartis says:

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,500+ biopharma pros reading Endpoints daily — and it's free.

Lina Gugucheva, NewAmsterdam Pharma CBO

Phar­ma group bets up to $1B-plus on the PhI­II res­ur­rec­tion of a once dead-and-buried LDL drug

Close to 5 years after then-Amgen R&D chief Sean Harper tamped the last spade of dirt on the last broadly focused CETP cholesterol drug — burying their $300 million upfront and the few remaining hopes for the class with it — the therapy has been fully resurrected. And today, the NewAmsterdam Pharma crew that did the Lazarus treatment on obicetrapib is taking another big step on the comeback trail with a €1 billion-plus regional licensing deal, complete with close to $150 million in upfront cash.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,500+ biopharma pros reading Endpoints daily — and it's free.

How pre­pared is bio­phar­ma for the cy­ber dooms­day?

One of the largest cyberattacks in history happened on a Friday, Eric Perakslis distinctly remembers.

Perakslis, who was head of Takeda’s R&D Data Sciences Institute and visiting faculty at Harvard Medical School at the time, had spent that morning completing a review on cybersecurity for the British Medical Journal. Moments after he turned it in, he heard back from the editor: “Have you heard what’s going on right now?”

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

(AP Photo/Gemunu Amarasinghe)

Some phar­ma com­pa­nies promise to cov­er abor­tion-re­lat­ed trav­el costs — while oth­ers won't go that far yet

As the US Department of Health and Human Services promises to support the millions of women who would now need to cross state lines to receive a legal abortion, a handful of pharma companies have said they will pick up employees’ travel expenses.

GSK, Sanofi, Johnson & Johnson, BeiGene, Alnylam and Gilead have all committed to covering abortion-related travel expenses just four days after the Supreme Court overturned Roe v. Wade and revoked women’s constitutional right to an abortion.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,500+ biopharma pros reading Endpoints daily — and it's free.

Aurobindo Pharma co-founders P. V. Ram Prasad Reddy (L) and K. Nityananda Reddy

Au­robindo Phar­ma re­ceives warn­ing let­ter from In­di­a's SEC fol­low­ing more FDA ques­tion marks

Indian-based generics manufacturer Aurobindo Pharma has been in the crosshairs of the FDA for several years now, but the company is also attracting attention from regulators within the subcontinent.

According to the Indian business news site Business Standard, a warning letter was sent to the company from the Securities Exchange Board of India, or SEBI.

The letter is related to disclosures made by the company on an ongoing FDA audit of the company’s Unit-1 API facility in Hyderabad, India as well as observations made by the US regulator between 2019 and 2022.

New Charles River Laboratories High Quality (HQ) Plasmid DNA Centre of Excellence at Bruntwood SciTech’s Alderley Park in Cheshire, United Kingdom. (Charles River)

Charles Riv­er Lab­o­ra­to­ries to start cell and gene ther­a­py man­u­fac­tur­ing at UK site in Sep­tem­ber

While Massachusetts-based Charles River Laboratories has been on an acquisition spree, they are not against planting their flag. The latest move by the company sees them crossing the pond to establish a manufacturing site in the UK.

The company on Tuesday opened its cell and gene therapy manufacturing center at Bruntwood SciTech’s Alderley Park in Cheshire, United Kingdom. The expansion follows Charles River’s acquisition of Cognate BioServices and Cobra Biologics in 2021 for $875 million. Cognate is a plasmid DNA, viral vector and cell therapy CDMO.

Bristol Myers Squibb (Alamy)

CVS re­sumes cov­er­age of block­buster blood thin­ner af­ter price drop fol­lows Jan­u­ary ex­clu­sion

Following some backlash from the American College of Cardiology and patients, Bristol Myers Squibb and Pfizer lowered the price of their blockbuster blood thinner Eliquis, thus ensuring that CVS Caremark would cover the drug after 6 months of it being off the major PBM’s formulary.

“Because we secured lower net costs for patients from negotiations with the drug manufacturer, Eliquis will be added back to our template formularies for the commercial segment effective July 1, 2022, and patient choices will be expanded,” CVS Health said in an emailed statement. “Anti-coagulant therapies are among the non-specialty products where we are seeing the fastest cost increases from drug manufacturers and we will continue to push back on unwarranted price increases.”

#Can­nes­Lions2022: Con­sumer health ex­ecs call on agen­cies to in­volve pa­tients in cre­ative process

CANNES — When Tamara Rogers joined GSK back in 2018, “science was king and R&D were the gods.” Now the global chief marketing officer of consumer healthcare wants to make room for another supreme being: the consumer.

As health and wellness becomes more relevant to consumers amid the pandemic, four health-focused executives called on marketers to involve patients in their creative process in a panel discussion at the Cannes Lions advertising creativity festival.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,500+ biopharma pros reading Endpoints daily — and it's free.